ASH 2019: Results of a study investigating Lenalidomide combined with Obinutuzumab for treatment of relapsed follicular or marginal zone lymphomas.
Home / Resource Library / A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma